Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Regeneron Pharmaceuticals
SCRI Development Innovations, LLC
Roswell Park Cancer Institute
University of Colorado, Denver
University of Colorado, Denver
Northwestern University
Yonsei University
InxMed (Shanghai) Co., Ltd.
Guangdong Provincial People's Hospital
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine